OncoTherapy Science, Inc. (JP:4564)
:4564
Top Page
OncoTherapy Science
(4564)
Select Model
Select Model
Rating:49Neutral
Price Target:
¥25.00
▲(19.05% Upside)
Action:ReiteratedDate:04/10/26
The score is held down primarily by weak financial performance (persistent losses and negative cash flow with reliance on financing). Technicals provide partial support with strong upward momentum, but overbought signals increase near-term pullback risk. Valuation is constrained by a negative P/E and the absence of dividend support.
Positive Factors
Focused oncology R&D
The company's dedicated focus on oncology and molecular-targeted approaches aligns it with structural, long-term demand in cancer therapeutics and diagnostics. Persistent unmet needs and genomics-driven target identification support durable R&D relevance and potential for sustainable product pipelines over years.
Negative Factors
Negative cash flow
Consistent negative operating and free cash flow requires repeated external financing to sustain operations. Over months this erodes optionality, increases dilution or interest burdens, and constrains the firm's ability to fund late-stage trials or scale commercialization without dilutive capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused oncology R&D
The company's dedicated focus on oncology and molecular-targeted approaches aligns it with structural, long-term demand in cancer therapeutics and diagnostics. Persistent unmet needs and genomics-driven target identification support durable R&D relevance and potential for sustainable product pipelines over years.
Read all positive factors
OncoTherapy Science (4564) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥10.36B
Dividend YieldN/A
Average Volume (3M)39.41M
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth99.87%
EPS Growth40.60%
CountryJP
Employees54
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.63
Shares Outstanding383,643,700
10 Day Avg. Volume60,218,049
30 Day Avg. Volume39,409,347
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)10.03
Price to Sales (P/S)9.75
P/FCF Ratio-8.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OncoTherapy Science Business Overview & Revenue Model
Company Description
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is i...
How the Company Makes Money
null...
OncoTherapy Science Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2022 | Mar 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 851.24M | 750.05M | 610.12M | 1.13B | 1.15B | 332.48M |
| Gross Profit | 164.71M | -12.76M | -177.72M | 41.69M | 113.91M | 19.54M |
| EBITDA | -842.06M | -811.92M | -1.29B | -1.09B | -2.04B | -1.59B |
| Net Income | -827.42M | -815.28M | -1.29B | -1.12B | -2.57B | -1.56B |
Balance Sheet | ||||||
| Total Assets | 1.53B | 1.16B | 867.27M | 1.51B | 2.69B | 3.37B |
| Cash, Cash Equivalents and Short-Term Investments | 1.23B | 833.88M | 527.66M | 1.12B | 1.84B | 2.90B |
| Total Debt | 37.14M | 51.07M | 106.85M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 449.62M | 426.09M | 513.61M | 656.27M | 704.97M | 291.28M |
| Stockholders Equity | 1.08B | 729.11M | 353.67M | 855.17M | 1.98B | 3.08B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -815.30M | -1.23B | -800.29M | -2.53B | -1.81B |
| Operating Cash Flow | 0.00 | -815.02M | -1.23B | -794.90M | -2.07B | -1.76B |
| Investing Cash Flow | 0.00 | -279.00K | -33.35M | -20.32M | -467.93M | -52.23M |
| Financing Cash Flow | 0.00 | 1.12B | 671.37M | 95.95M | 1.48B | 0.00 |
OncoTherapy Science Technical Analysis
Positive
21.00
Price Trends
21.46
Positive
21.52
Positive
23.97
Positive
Market Momentum
1.08
Negative
76.17
Negative
85.19
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Positive. The current price of 21 is below the 20-day moving average (MA) of 22.75, below the 50-day MA of 21.46, and below the 200-day MA of 23.97, indicating a bullish trend. The MACD of 1.08 indicates Negative momentum. The RSI at 76.17 is Negative, neither overbought nor oversold. The STOCH value of 85.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4564.
OncoTherapy Science Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | ¥75.68B | -20.18 | ― | ― | -9.04% | 13.09% | |
54 Neutral | ¥20.74B | 87.60 | ― | ― | 9.87% | -24.41% | |
52 Neutral | ¥11.83B | -12.44 | -26.70% | ― | 172.39% | 8.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥10.36B | -7.89 | -63.25% | ― | 99.87% | 40.60% | |
48 Neutral | ¥91.85B | -5.96 | -19.31% | ― | -1.96% | -64.18% | |
46 Neutral | ¥167.48B | -57.13 | -10.16% | ― | -62.47% | -134.06% |
* Healthcare Sector Average
JP:4564
OncoTherapy Science
25.00
2.00
8.70%
JP:4587
Peptidream
1,229.00
-654.00
-34.73%
JP:4565
Sosei Group
1,024.00
272.00
36.17%
JP:4571
NanoCarrier Co., Ltd.
148.00
23.00
18.40%
JP:4579
RaQualia Pharma Inc.
835.00
500.00
149.25%
JP:4588
Oncolys BioPharma, Inc.
2,516.00
1,998.00
385.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.